Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Heptares

This page shows the latest Heptares news and features for those working in and with pharma, biotech and healthcare.

GSK signs collaboration deal with Ligand targeting neurological disorders

GSK signs collaboration deal with Ligand targeting neurological disorders

products. Another deal – signed with Sosei Heptares this week – will see GSK collaborate on the discovery and development of a small molecule target for inflammatory bowel disease and other gastrointestinal immune

Latest news

More from news
Approximately 3 fully matching, plus 7 partially matching documents found.

Latest Intelligence

  • Where next in Alzheimer’s disease R&D? Where next in Alzheimer’s disease R&D?

    Whereas in the past the sector had “a very singular focus on amyloid”, Sosei Heptares’ chief R&D officer Malcolm Weir said he now thinks it is looking at targets “in ... Other groups, including Sosei Heptares, are working on novel ways to modify

  • 30 Women Leaders in UK Healthcare 30 Women Leaders in UK Healthcare

    Dr Fiona Marshall has joined MSD from Heptares Therapeutics, the UK biotech company she co-founded more than a decade ago, which was acquired by Sosei in 2015.

  • Deal Watch March 2017 Deal Watch March 2017

    rights to Heptares’ G protein-coupled receptor product for pain relief. ... 20. Heptares/ Sosei Group. Daiichi Sankyo. Licence. G protein coupled receptor for pain relief.

  • Deal Watch April 2016 Deal Watch April 2016

    Allergan must have known for some time that the Pfizer acquisition was likely to collapse because on the same day as the announcement, Allergan announced a $3.3bn deal with Heptares ... 9, 800. Heptares (JP). Allergan (IE). License and collaboration.

  • Deal Watch November 2015 Deal Watch November 2015

    455. Heptares. Teva. Licence drug-discovery agreement. Small molecule calcitonin gene-related peptide (CGRP) antagonists for migraine. ... 225. Heptares. Pfizer. Strategic discovery collaboration. New therapeutics against up to 10 GPCR targets across

More from intelligence
Approximately 1 fully matching, plus 9 partially matching documents found.

Latest appointments

  • Metrion Biosciences adds to its board Metrion Biosciences adds to its board

    Dr Kenny is currently chief business officer of Heptares Therapeutics, now part of Sosei Group, and was previously vice president, drug discovery at Takeda.

  • Sosei appoints chief operating officer Sosei appoints chief operating officer

    He has served as a non-executive director at Sosei since 2010, and has since worked at Syngene International, where he was chief executive and executive director, and Heptares Therapeutics, where

  • Former Amgen EVP Roger Perlmutter joins Heptares board Former Amgen EVP Roger Perlmutter joins Heptares board

    Also has experience at Merck &Co. Heptares has appointed Amgen's former executive VP, R&D, Dr Roger Perlmutter, to its board of directors. ... Dr Perlmutter said: “Heptares has pioneered structure determination in GPCRs, and has used this information

More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....

Quick links